The two-shot vaccine from BioNTech and Pfizer gained official approval for people 16 and older in the European Union on Monday, two days after Switzerland approved its use through a normal procedure.
The European Medicines Agency recommended Pfizer-BioNTech’s coronavirus vaccine Comirnaty® (BNT162b2) throughout the 27-nation E.U. based on its findings — similar to those from Swiss medical regulator Swissmedic on Saturday — that the level of protection afforded seven days after the second injection of the vaccine is more than 90% effective against COVID-19.
